All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china
单位:[1]Peking University People’sHospital, Beijing, China[2]Peking University First Hospital, Beijing, China[3]Guangzhou Eighth People’s Hospital, Guangzhou, China[4]Beijing YouAn Hospital, Beijing, China[5]The First Affiliated Hospital of MedicalSchool of Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[6]Sichuan ProvincialPeople’s Hospital, Chengdu, China四川省人民医院[7]West China Hospital, SichuanUniversity, Chengdu, China四川大学华西医院[8]Xiangya Hospital, Central South University,Changsha, China[9]Henan People’s Hospital, Zhengzhou, China[10]Liuzhou People’s Hospital, Liuzhou, China[11]Jiangsu People’s Hospital,Nanjing, China江苏省人民医院[12]Zhenjiang No.3 People’s Hospital, Zhenjiang, China[13]The third People’s Hospital of Shenzhen, Shenzhen, China[14]RuijinHospital, Shanghai Jiaotong University School of Medicine, Shanghai,China[15]People’s Liberation Army Bayi Hospital, Nanjing, China[16]Shenyang Sixth People’s Hospital, Shenyang, China[17]The 2nd XiangyaHospital of Central South University, Changsha, China[18]Xixi Hospital ofHangzhou, Hangzhou, China[19]Tongji Medical College of HUST, Wuhan,China[20]The First Hospital of Jilin University, Changchun, China[21]BaojiCenter Hospital, Baoji, China[22]Beijing Ditan Hospital, Beijing, China[23]Huashan Hospital Affiliated to Fudan University, Shanghai, China[24]Chongqing Medical University No.1 Affiliated Hospital, Chongqing,China重庆医科大学附属第一医院[25]The Second Hospital of Nanjing, Nanjing, China[26]FujianFuzhou Municipal Infectious Disease Hospital, Fuzhou, China[27]No.1Affiliated Hospital of Xi’an Jiaotong University, Xian, China[28]The FirstAffiliated Hospital of Guangxi Medical University, Nanning, China[29]Beijing Friendship Hospital, Capital Medical University, Beijing, China首都医科大学附属北京友谊医院[30]Wuhan Union Hospital, Wuhan, China华中科技大学同济医学院附属协和医院[31]Shanghai Public HealthClinical Center, Shanghai, China[32]Foshan No.1 People’s Hospital,Foshan, China[33]The Third Hospital of Hebei Medical University,Shijiazhuang, China[34]Wuhan University Renmin Hospital, Wuhan,China[35]The Affiliated Hospital of Guizhou Medical University, Guiyang,China[36]The Second Affiliated Hospital of Chongqing Medical University,Chongqing, China[37]PLA 302 Hospital, Beijing, China[38]The firstAffiliated Hospital of Harbin Medical University, Harbin, China[39]Fuzhou General Hospital of Nanjing Military Command, Fuzhou,China[40]Tang du Hospital, fourth military Medical University, Xian,China[41]Nanfang Hospital, Nanfang Medical University, Guangzhou,China[42]The 85 branch of the Chinese people’s Liberation Army Hospital,shanghai, China[43]Ascletis BioScience Co., Ltd, Hangzhou, China
第一作者单位:[1]Peking University People’sHospital, Beijing, China
推荐引用方式(GB/T 7714):
Lai Wei,xiaoyuan Xu,yujuan Guan,et al.All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china[J].JOURNAL of HEPATOLOGY.2019,70(1):E247-E247.doi:10.1016/S0618-8278(19)30467-0.
APA:
Lai Wei,xiaoyuan Xu,yujuan Guan,sujun Zheng,Ji-Fang Sheng...&Jinzi Wu..(2019).All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china.JOURNAL of HEPATOLOGY,70,(1)
MLA:
Lai Wei,et al."All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china".JOURNAL of HEPATOLOGY 70..1(2019):E247-E247